United States · Exchanges & live quotes · Nasdaq

Pfizer's Eliquis Price Gains Cover COVID Drop: Rapid Earnings Reaction

Published by Nasdaq · United States 1 h ago

Key PointsRevenue was flat at $16.6 billion, with COVID and Prevnar sales falling while Eliquis, Padcev, Vyndaqel, Nurtec, and Lorbrena grew.

Read the full article on Nasdaq Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.nasdaq.com)

Also worth reading

Dubai Benchmark Slips Into Contango for the First Time Since July

Ballot scanner issues disrupt voting in New York’s Westchester County

Bitcoin ETF Tracker

Here’s How Much Traders Expect Palantir Stock to Move After Earnings

Cboe Global Markets

Nasdaq and S&P 500 Index Lose Momentum, Pull Down Market

Introducing new self-learning context enrichment in Knowledge Catalog